These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 3042042)

  • 1. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease.
    Sullivan KM; Witherspoon RP; Storb R; Deeg HJ; Dahlberg S; Sanders JE; Appelbaum FR; Doney KC; Weiden P; Anasetti C
    Blood; 1988 Aug; 72(2):555-61. PubMed ID: 3042042
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation.
    Sullivan KM; Witherspoon RP; Storb R; Weiden P; Flournoy N; Dahlberg S; Deeg HJ; Sanders JE; Doney KC; Appelbaum FR
    Blood; 1988 Aug; 72(2):546-54. PubMed ID: 3042041
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone.
    Koc S; Leisenring W; Flowers ME; Anasetti C; Deeg HJ; Nash RA; Sanders JE; Witherspoon RP; Storb R; Appelbaum FR; Martin PJ
    Blood; 2002 Jul; 100(1):48-51. PubMed ID: 12070007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prevention of acute graft-vs.-host disease: effect on chronic graft-vs.-host disease and long-term survival.
    Ross M; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM; Smith EP; Snyder DS; Stein AS; Wong RM; Forman SJ; Blume KG; Chao NJ
    Biol Blood Marrow Transplant; 1999; 5(5):285-91. PubMed ID: 10534058
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Isolated thrombocytopenia after allogeneic bone marrow transplantation: existence of transient and chronic thrombocytopenic syndromes.
    First LR; Smith BR; Lipton J; Nathan DG; Parkman R; Rappeport JM
    Blood; 1985 Feb; 65(2):368-74. PubMed ID: 3881142
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease.
    Arora M; Wagner JE; Davies SM; Blazar BR; Defor T; Enright H; Miller WJ; Weisdorf DF
    Biol Blood Marrow Transplant; 2001; 7(5):265-73. PubMed ID: 11400948
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone.
    Nademanee A; Schmidt GM; Parker P; Dagis AC; Stein A; Snyder DS; O'Donnell M; Smith EP; Stepan DE; Molina A
    Blood; 1995 Aug; 86(3):1228-34. PubMed ID: 7620176
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of cyclosporine and methylprednisolone dose used for prophylaxis and therapy of graft-versus-host disease on survival and relapse after allogeneic bone marrow transplantation.
    Michallet M; Perrin MC; Belhabri A; Molina L; Nicolini F; Tigaud JD; Sotto JJ; Guyotat D; Fière D; Archimbaud E
    Bone Marrow Transplant; 1999 Jan; 23(2):145-50. PubMed ID: 10197799
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease.
    Chao NJ; Schmidt GM; Niland JC; Amylon MD; Dagis AC; Long GD; Nademanee AP; Negrin RS; O'Donnell MR; Parker PM
    N Engl J Med; 1993 Oct; 329(17):1225-30. PubMed ID: 8413388
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapy of chronic graft-v-host disease in a rat model.
    Vogelsang GB; Hess AD; Friedman KJ; Santos GW
    Blood; 1989 Jul; 74(1):507-11. PubMed ID: 2752128
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What role for prednisone in prevention of acute graft-versus-host disease in patients undergoing marrow transplants?
    Storb R; Pepe M; Anasetti C; Appelbaum FR; Beatty P; Doney K; Martin P; Stewart P; Sullivan KM; Witherspoon R
    Blood; 1990 Sep; 76(5):1037-45. PubMed ID: 2203481
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cyclosporine and methylprednisolone after allogeneic marrow transplantation: association between low cyclosporine concentration and risk of acute graft-versus-host disease.
    Przepiorka D; Shapiro S; Schwinghammer TL; Bloom EJ; Rosenfeld CS; Shadduck RK; Venkataramanan R
    Bone Marrow Transplant; 1991 Jun; 7(6):461-5. PubMed ID: 1873593
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination graft-versus-host disease prophylaxis using immunotoxin (anti-CD5-RTA [Xomazyme-CD5]) plus methotrexate and cyclosporine or prednisone after unrelated donor marrow transplantation.
    Weisdorf D; Filipovich A; McGlave P; Ramsay N; Kersey J; Miller W; Blazar B
    Bone Marrow Transplant; 1993 Nov; 12(5):531-6. PubMed ID: 8298565
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased risk of leukemia relapse with high-dose cyclosporine A after allogeneic marrow transplantation for acute leukemia.
    Bacigalupo A; Van Lint MT; Occhini D; Gualandi F; Lamparelli T; Sogno G; Tedone E; Frassoni F; Tong J; Marmont AM
    Blood; 1991 Apr; 77(7):1423-8. PubMed ID: 2009366
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Six weeks of continuous intravenous cyclosporine and short-course methotrexate as prophylaxis for acute graft-versus-host disease after allogeneic bone marrow transplantation.
    Beelen DW; Quabeck K; Kaiser B; Wiefelspütz J; Scheulen ME; Graeven U; Grosse-Wilde H; Sayer HG; Schaefer UW
    Transplantation; 1990 Sep; 50(3):421-7. PubMed ID: 2402791
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression.
    Sullivan KM; Shulman HM; Storb R; Weiden PL; Witherspoon RP; McDonald GB; Schubert MM; Atkinson K; Thomas ED
    Blood; 1981 Feb; 57(2):267-76. PubMed ID: 7004534
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclosporine toxicity: the effect of combined therapy using cyclosporine, azathioprine, and prednisone.
    Lorber MI; Flechner SM; Van Buren CT; Sorensen K; Kerman RH; Kahan BD
    Am J Kidney Dis; 1987 Jun; 9(6):476-84. PubMed ID: 3296744
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine.
    Kennedy MS; Deeg HJ; Storb R; Doney K; Sullivan KM; Witherspoon RP; Appelbaum FR; Stewart P; Sanders J; Buckner CD
    Am J Med; 1985 Jun; 78(6 Pt 1):978-83. PubMed ID: 3893112
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marrow transplantation for severe aplastic anemia: methotrexate alone compared with a combination of methotrexate and cyclosporine for prevention of acute graft-versus-host disease.
    Storb R; Deeg HJ; Farewell V; Doney K; Appelbaum F; Beatty P; Bensinger W; Buckner CD; Clift R; Hansen J
    Blood; 1986 Jul; 68(1):119-25. PubMed ID: 3521761
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.